文献速递临床试验与 GCP基础与转化研究新药、器械与细胞基因治疗研发

靶向CD22的CAR-T细胞疗法治疗CD19靶向CAR-T细胞疗法后进展的大B细胞淋巴瘤:一项剂量探索1期研究

CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
PubMed 文献 · Lancet · 2024-07-09

BACKGROUND: Outcomes are poor for patients with large B-cell lymphoma who relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19).…

要点

  • 38例(95%)成功制备CAR-T产品,37例(97%)为CAR19后复发。
  • 接受最大耐受剂量的29例患者未出现剂量限制性毒性或≥3级上述毒性。

核心结论

  • 本试验将CD22确定为大B细胞淋巴瘤的免疫治疗靶点,并显示CAR22在CAR19治疗后疾病进展患者中具有持久的临床活性。
  • 作者指出,尽管结果令人鼓舞,但须认识到这是1期剂量探索研究;需进一步研究以确定长期疗效并界定最获益的患者亚组。

研究设计与样本

  • 纳入年龄≥18岁、CAR19后复发或CD19阴性大B细胞淋巴瘤的成人患者。
  • 主要终点为生产可行性、以不良事件和剂量限制性毒性发生率和严重程度衡量的安全性,以及最大耐受剂量(即推荐2期剂量)的确定。
  • 研究注册于ClinicalTrials.gov(NCT04088890),处于活跃状态但已停止入组。

主要发现

  • 2019年10月17日至2022年10月19日,共评估41例患者资格,其中1例撤回;40例接受白细胞分离,38例(95%)成功制备CAR T细胞产品。
  • 中位年龄65岁(范围25-84),17例(45%)为女性,32例(84%)治疗前乳酸脱氢酶升高,11例(29%)对所有既往治疗难治,既往治疗中位线数为4线(范围3-8)。
  • 38例接受治疗的患者中,37例(97%)为既往CAR19后复发。

临床怎么用

  • 作者认为,本试验将CD22确定为大B细胞淋巴瘤的免疫治疗靶点,并显示CAR22在CAR19治疗后疾病进展患者中具有持久的临床活性。
  • 作者指出,尽管结果令人鼓舞,但须认识到这是1期剂量探索研究;需进一步研究以确定长期疗效并界定最获益的患者亚组。

局限性

  • 作者指出,尽管结果令人鼓舞,但须认识到这是1期剂量探索研究。
  • 需进一步研究以确定长期疗效并界定最获益的患者亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcomes are poor for patients with large B-cell lymphoma who relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly universally expressed B-cell surface antigen and the efficacy of a CD22-directed CAR T-cell therapy (CAR22) in large B-cell lymphoma is unknown, which was what we aimed to examine in this study. METHODS: In this single centre, open-label, dose-escalation phase 1 trial, we intravenously administered CAR22 at two dose levels (1 million and 3 million CAR22-positive T cells per kg of bodyweight) to adult patients (aged ≥18 years) who relapsed after CAR19 or had CD19-negative large B-cell lymphoma. The primary endpoints were manufacturing feasibility, safety measured by the incidence and severity of adverse events and dose-limiting toxicities, and identification of the maximum tolerated dose (ie, the recommended phase 2 dose). This study is registered with ClinicalTrials.gov (NCT04088890) and is active, but closed for enrolment. FINDINGS: From Oct 17, 2019, to Oct 19, 2022, a total of 41 patients were assessed for eligibility; however, one patient withdrew. 40 patients underwent leukapheresis and 38 (95%) had CAR T-cell products manufactured successfully. The median age was 65 years (range 25-84), 17 (45%) were women, 32 (84%) had elevated pretreatment lactate dehydrogenase, 11 (29%) had refractory disease to all previous therapies, and patients had received a median of four lines of previous therapy (range 3-8). Of the 38 patients treated, 37 (97%) had relapsed after previous CAR19. The identified maximum tolerated dose was 1 million CAR T cells per kg. Of 29 patients who received the maximum tolerated dose, no patients developed a dose-limiting toxicity or grade 3 or higher cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or immune effector cell-associated haemophagocytic lymphohistiocytosis-like syndrome. INTERPRETATION: This trial identifies CD22 as an immunotherapeutic target in large B-cell lymphoma and demonstrates the durable clinical activity of CAR22 in patients with disease progression after CAR19 therapy. Although these findings are promising, it is essential to recognise that this is a phase 1 dose-finding study. Further investigations are warranted to establish the long-term efficacy and to delineate the patient subgroups that will derive the most benefit from this therapeutic approach. FUNDING: National Cancer Institute, National Institutes of Health, Stanford Cancer Institute, Leukemia & Lymphoma Society, Parker Institute for Cancer Immunotherapy, Lymph & Co, and the European Hematology Association.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Frank MJ, Baird JH, Kramer AM, et al. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet. 2024. PMID: 38996463. doi:10.1016/S0140-6736(24)00746-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。